ISPOR is coming to Canada this year, taking place in Montreal, May 5th to 8th. Broadstreet is pleased to be involved in six studies being presented on subjects ranging from the clinical impact of discontinuation of sodium-glucose transport protein 2 inhibitors  in type 2 diabetes mellitus to the potential for using surrogate endpoints for overall survival among patients with non-small cell lung cancer.

We are delighted to be presenting some of our own research exploring synthesis and reporting guidelines for topics where a formal meta-analysis would be inappropriate. The work identifying gaps and proposing strategies to address them with respect to synthesizing data from natural history and burden of illness studies served to inform the development of an observational study evidence synthesis and reporting checklist. In literature reviews of observational data, it can be difficult to anticipate the breadth and heterogeneity of data that will be identified. Our proposed checklist will help standardize reporting on a the sorts of wider evidence bases which are valuable in understanding drivers of heterogeneity in observational study data.

The poster about this project, titled “Drivers of Variability Exploration (DiVE!): A Review to Inform A Proposed Observational Study Evidence Synthesis and Reporting Checklist” will be viewable during poster session 5 on Friday, May 16th.

We invite you to check out all our posters:

In Session 1 on Wednesday, May 14^th:

HTA10 – Patient Voice in Rare Disease Health Technology Assessments: Recent Trends in the Use of Qualitative Research in Reimbursement Submissions to Canada’s Drug Agency

Jessica S. Dunne, Evelyn C. Griffin, Cassandra L. Debard, Lauren C. Powell
Broadstreet, Vancouver, BC, Canada

In Session 2 on Wednesday, May 14th:

CO58 – PFS and ORR as surrogate endpoints for OS among patients with ROS1+ locally advanced or metastatic non-small cell lung cancer receiving ROS1 TKIs

Ellen E. Korol, MSc¹, Yong Yuan, PhD², Juan Pablo Diaz-Martinez, PhD³, Adam Lee, MSc⁴, Christophe Y Calvet, PhD⁵, David Ross Camidge, PhD⁶, Sarah Goring, MSc^1
1Broadstreet HEOR, Vancouver, BC, Canada, ²Bristol Myers Squibb, Princeton, NJ, USA, ³Broadstreet, Vancouver, BC, Canada, ⁴Bristol Myers Squibb, Uxbridge, United Kingdom, ⁵Bristol Myers Squibb, Princeton, BC, Canada, ⁶Cancer Center, University of Colorado, Aurora, CO, USA.

In Session 3 on Thursday, May 15^th:

CO109 – The Clinical Impact of Discontinuation of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2is): A Targeted Literature Review

Alison M. Bjornson, MSc¹, Lindsay G. Bengtson, PhD², Shiraz El Adam, MSc¹, Shelagh M. Szabo, MSc¹, Bonnie M. Donato, PhD^2;
1Broadstreet HEOR, Vancouver, BC, Canada, ²Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA

EE299 – Cost Per PFS-Based Responder for TKI-Naive Patients Receiving Repotrectinib or Entrectinib in ROS1 Fusion Positive Non-Small Cell Lung Cancer (NSCLC) in the United States (US)

Reginald Villacorta, PhD¹, Rick Szymialis, BSc¹, Yong Yuan, PhD¹, Matthew Martin, MSc², Karissa M. Johnston, BSc, MSc, PhD^2
1BMS, New Brunswick, NJ, USA, ²Broadstreet Health Economics and Outcomes Research, Vancouver, BC, Canada

In Session 4 on Thursday May 15^th:

CO158 – Late-Stage Outcomes in Patients with Limb-Girdle Muscular Dystrophy (LGMD) Sarcoglycanopathy Subtypes: A Systematic Review

Sharanya Murty,¹ Antoinette Cheung,² André Müller-York,¹ Lavanya Sudharshan,¹ Andrew R. Kennedy,² Shelagh M. Szabo^2
1Sarepta Therapeutics, Inc., Cambridge, MA USA, ²Broadstreet HEOR, Vancouver BC Canada

In Session 5 on Wednesday, May 8^th:

SA67 – Drivers of Variability Exploration (DiVE!): A Review to Inform A Proposed Observational Study Evidence Synthesis and Reporting Checklist

Alison M. Bjornson, MSc¹, Antoinette Cheung, MPH¹, Karissa M. Johnston, BSc, MSc, PhD¹, Shelagh Szabo, MSc^1
1Broadstreet HEOR, Vancouver, BC, Canada

If you have questions about any of these projects or how Broadstreet can support the development of your HEOR projects, please get in touch at [email protected].